Results 181 to 190 of about 16,133 (222)

Human CYP2B6

Pharmacogenetics, 1999
Human cytochrome (CYP)2B6 cDNA was cloned and expressed in bacteria and in yeast. Its expression in Saccharomyces cerevisiae enabled us to obtain, at a high level, an active yeast-expressed CYP2B6 protein, so as to assess its role in the metabolism of ethoxyresorufin, pentoxyresorufin, benzyloxyresorufin, ethoxycoumarin, testosterone and ...
L, Gervot, B, Rochat, J C, Gautier, F, Bohnenstengel, H, Kroemer, V, de Berardinis, H, Martin, P, Beaune, I, de Waziers   +8 more
openaire   +2 more sources

Identification of miRNAs that regulate human CYP2B6 expression

Drug Metabolism and Pharmacokinetics, 2021
Human hepatic cytochrome P450 2B6 (CYP2B6) expressed is responsible for the metabolism of many drugs, such as cyclophosphamide, ifosfamid, and efavirenz. In the present study, the correlation between CYP2B6 mRNA and protein levels in human liver samples was found to be moderate, indicating a contribution of posttranscriptional regulation of CYP2B6 ...
Masataka, Nakano, Chika, Iwakami, Tatsuki, Fukami, Miki, Nakajima   +3 more
openaire   +2 more sources

Artemisinin–a possible CYP2B6 probe substrate?

Biopharmaceutics & Drug Disposition, 2009
AbstractAim. To comparein vitrometabolism rates for artemisinin and the CYP2B6 substrates, bupropion, propofol and efavirenz in human liver microsomes.Methods. Rate constants of artemisinin, bupropion, propofol and efavirenz metabolism by human liver microsomes from a panel of 12 donors, with different levels of CYP2B6 activity, were estimated in ...
Sara, Asimus, Michael, Ashton
openaire   +2 more sources

Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation [PDF]

Pharmacogenomics Journal, 2003
The role of polymorphic CYP2B6 in cyclophosphamide (CPA) bioactivation was investigated in human liver microsomes. A total of 67 human liver specimens were first genotyped with respect to the CYP2B6*5 and CYP2B6*6 variant alleles. CYP2B6 apoprotein levels in 55 liver microsomal preparations were assessed by immunoblotting.
H-J, Xie, U, Yasar, S, Lundgren, L, Griskevicius, Y, Terelius, M, Hassan, A, Rane   +6 more
exaly   +3 more sources

Psoralen, a mechanism-based inactivator of CYP2B6

Chemico-Biological Interactions, 2015
Furanocoumarin compound psoralen (PRN) is a major active ingredient found in herbaceous plants. PRN has been used for the treatment of various dermal diseases in China. We evaluated the inhibitory effect of PRN on cytochrome P450 2B6 (CYP2B6) and found that PRN induced a time-, concentration-, and NADPH-dependent inactivation of CYP2B6 with the values ...
Lin, Ji, Dan, Lu, Jiaojiao, Cao, Liwei, Zheng, Ying, Peng, Jiang, Zheng   +5 more
openaire   +2 more sources

Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels

Pharmacogenetics and Genomics, 2013
(S)-Methadone, metabolized mainly by CYP2B6, shows a wide interindividual variability in its pharmacokinetics and pharmacodynamics.Resequencing of the CYP2B6 gene was performed in 12 and 35 selected individuals with high (S)-methadone plasma exposure and low (S)-methadone plasma exposure, respectively, from a previously described cohort of 276 patients
Dobrinas, Maria, Crettol, Séverine, Oneda, Beatrice, Lahyani, Rachel, Rotger, Margalida, Choong, Eva, Lubomirov, Rubin, Csajka, Chantal, Eap, Chin B   +8 more
openaire   +2 more sources

Examination of purported probes of human CYP2B6

Pharmacogenetics, 1997
7-Ethoxy-4-trifluoromethylcoumarin (7-EFC) was examined as a substrate for cytochrome P450 (P450) in microsomes from human livers and expressed in B-lymphoblastoid cells. The O-deethylation of 7-EFC to 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) varied over a liver bank (n = 19) by a factor of 13 (40-507 pmol min-1 mg-1 protein). When compared with the
S, Ekins, M, VandenBranden, B J, Ring, S A, Wrighton   +3 more
openaire   +2 more sources